Synergistic Dual-Targeting Bacterial Extracellular Vesicles Delivering Paclitaxel for Precision Glioblastoma Therapy

Glioblastoma (GBM) poses significant therapeutic challenges due to the restrictive blood-brain barrier (BBB) and blood-tumor barrier (BTB). To overcome these obstacles, we developed a dual-targeted nanodelivery system (AT-BEVs) based on engineered bacterial extracellular vesicles (BEVs). By integrating Angiopep-2 for LRP-1-mediated BBB transport and TAT peptide for enhanced tumor penetration, AT-BEVs achieve sequential barrier and tumor targeting. This platform effectively encapsulates hydrophobic chemotherapeutics such as paclitaxel (PTX) and enables tumor microenvironment-responsive drug release. In orthotopic GBM models, AT-BEVs loaded with PTX (AT-BEVs@PTX) showed improved brain tumor accumulation, inhibited tumor progression, and significantly extended survival. Our work presents a promising strategy to overcome dual delivery barriers in GBM and offers translational potential for targeted cancer therapy.

Authors

Institutions

Publication Details

Journal
Nano Letters
Published
2025-10-15
DOI
https://doi.org/10.1021/acs.nanolett.5c03032
Citations
1
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.81
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Synergistic Dual-Targeting Bacterial Extracellular Vesicles Delivering Paclitaxel for Precision Glioblastoma Therapy

Zongqiang Lv, Han Liu, Rong Li, Chao Chen et al.
1 citations
Nano Letters
Extracellular vesicles in disease
0.81
article

Synergistic Dual-Targeting Bacterial Extracellular Vesicles Delivering Paclitaxel for Precision Glioblastoma Therapy

Zongqiang Lv, Han Liu, Rong Li, Chao Chen, Hongxiang Wang, Ning Luo, Juxiang Chen, Yong Yan, Jiacan Su, Bo Sun, Peiran Song
article en
1 citations

Abstract

Glioblastoma (GBM) poses significant therapeutic challenges due to the restrictive blood-brain barrier (BBB) and blood-tumor barrier (BTB). To overcome these obstacles, we developed a dual-targeted nanodelivery system (AT-BEVs) based on engineered bacterial extracellular vesicles (BEVs). By integrating Angiopep-2 for LRP-1-mediated BBB transport and TAT peptide for enhanced tumor penetration, AT-BEVs achieve sequential barrier and tumor targeting. This platform effectively encapsulates hydrophobic chemotherapeutics such as paclitaxel (PTX) and enables tumor microenvironment-responsive drug release. In orthotopic GBM models, AT-BEVs loaded with PTX (AT-BEVs@PTX) showed improved brain tumor accumulation, inhibited tumor progression, and significantly extended survival. Our work presents a promising strategy to overcome dual delivery barriers in GBM and offers translational potential for targeted cancer therapy.

Nano LettersVol. 25(43)
Shanghai University (CN), Tongji University (CN), Translational Research Institute (AU), Second Military Medical University (CN), Shanghai Jiao Tong University (CN), XinHua Hospital (CN), Soochow University (CN), MED Institute (US), People's Liberation Army 401 Hospital (CN), Changhai Hospital (CN), 81th Hospital of PLA (CN), Center for Translational Molecular Medicine (NL), Central Hospital of Wuhan (CN), Nanjing Second Hospital (CN), Wuhan General Hospital of Guangzhou (CN), General Hospital of Central Theater Command
Openalex Percentile: Top 22%
Extracellular vesicles in disease
0.81
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.